摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R)-4-Benzyl-2-(4-fluorobenzyl)piperazine | 192661-22-6

中文名称
——
中文别名
——
英文名称
(2R)-4-Benzyl-2-(4-fluorobenzyl)piperazine
英文别名
(3R)-1-benzyl-3-(4-fluorobenzyl)piperazine;(3R)-1-benzyl-3-[(4-fluorophenyl)methyl]piperazine
(2R)-4-Benzyl-2-(4-fluorobenzyl)piperazine化学式
CAS
192661-22-6
化学式
C18H21FN2
mdl
——
分子量
284.377
InChiKey
WJYQNRDEKLBEKD-GOSISDBHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    396.0±32.0 °C(Predicted)
  • 密度:
    1.117±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    (2R)-4-Benzyl-2-(4-fluorobenzyl)piperazinepalladium dihydroxide 氢气1-羟基苯并三唑1-(3-二甲基氨基丙基)-3-乙基碳二亚胺N,N-二异丙基乙胺 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 生成 {(R)-1-(2-Fluoro-benzyl)-3-[(R)-2-(4-fluoro-benzyl)-piperazin-1-yl]-3-oxo-propyl}-carbamic acid tert-butyl ester
    参考文献:
    名称:
    Substituted piperazines as novel dipeptidyl peptidase IV inhibitors
    摘要:
    Incorporation of a fluorophenyl beta-amino amide moiety into piperazine screening lead 2 has resulted in the discovery of a structurally novel series of potent and selective DP-IV inhibitors. Simplification of the molecule and incorporation of multiple fluorine atoms on the phenyl ring has provided low molecular weight analogs such as compound 32, which is a 19 nM DP-IV inhibitor with >4000-fold selectivity over QPP. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.06.065
  • 作为产物:
    描述:
    (3R)-1-Benzyl-3-(4-fluorobenzyl)piperazine-2,5-dione 以 四氢呋喃 为溶剂, 生成 (2R)-4-Benzyl-2-(4-fluorobenzyl)piperazine
    参考文献:
    名称:
    Piperazine derivatives as tachykinin antagonists
    摘要:
    这个申请是PCT/JP96/03641的371文件,提交日期为1996年12月12日。
    公开号:
    US06087357A1
点击查看最新优质反应信息

文献信息

  • Piperazine derivatives
    申请人:Take Kazuhiko
    公开号:US20060014948A1
    公开(公告)日:2006-01-19
    This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.
    这项发明涉及以下式的哌嗪生物: 其中每个符号如描述中所定义,并且其药用可接受盐,制备方法,包含相同物质的药物组合物,以及用于治疗或预防人类或动物的Tachykinin介导疾病的用途。
  • Substituted imidazole compound and use thereof
    申请人:Kuroita Takanobu
    公开号:US20090227560A1
    公开(公告)日:2009-09-10
    The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof. The compound of the present invention has a superior renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension, and the like.
    本发明涉及一种由以下式表示的化合物:其中每个符号如描述中所定义,或其盐或前药。本发明的化合物具有优越的肾素抑制活性,因此可用作预防或治疗高血压、由高血压引起的各种器官损伤等的药物。
  • PIPERAZINE DERIVATIVES
    申请人:Take Kazuhiko
    公开号:US20070123532A1
    公开(公告)日:2007-05-31
    This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.
    本发明涉及以下式的哌嗪生物:其中每个符号如描述中所定义,以及其药学上可接受的盐,制备过程,包含它们的制药组合物,以及将其用于治疗或预防人类或动物的缓激肽介导疾病的用途。
  • Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
    申请人:Kuroita Takanobu
    公开号:US20100121048A1
    公开(公告)日:2010-05-13
    The present invention relates to a compound represented by the formula: (I) wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent (s); U, V and W are each independently C or N, provided that when any one of U, V and W is N, then the others should be C; Ra and Rb are each independently a cyclic group optionally having substituent(s), a C 1-10 alkyl group optionally having substituent(s), a C 2-10 alkenyl group optionally having substituent(s), or a C 2-10 alkynyl group optionally having substituent(s); X is a bond, or a spacer having 1 to 6 atoms in the main chain; Y is a spacer having 1 to 6 atoms in the main chain; Rc is a hydrocarbon group optionally containing heteroatom(s) as the constituting atom(s), which optionally has substituent(s); m and n are each independently 1 or 2; and ring B optionally further has substituent(s), or a salt thereof. The compound of the present invention has excellent renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension, and the like.
    本发明涉及一种由式(I)表示的化合物:其中,环A是一种5或6成员的芳香杂环,可选地具有取代基;U、V和W分别独立地为C或N,但当U、V和W中的任何一个为N时,其他的应为C;Ra和Rb分别独立地为一个环状基团,可选地具有取代基;一个C1-10烷基,可选地具有取代基;一个C2-10烯基,可选地具有取代基;或一个C2-10炔基,可选地具有取代基;X是一条键或具有1到6个原子的主链间隔;Y是具有1到6个原子的主链间隔;Rc是一个含有杂原子作为构成原子的碳氢基团,可选地具有取代基;m和n分别独立地为1或2;环B可选地具有取代基,或其盐。本发明的化合物具有优异的肾素抑制活性,因此可用作预防或治疗高血压、高血压引起的各种器官损伤等的药物。
  • PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0873320B1
    公开(公告)日:2002-06-12
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫